Clinical management of acute neuroleptic-induced extrapyramidal syndromes.
Keepers
G A
GA
Casey
D E
DE
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000367:Age Factors; D017109:Akathisia, Drug-Induced; D000547:Amantadine / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000009:adverse effects*; D001480:Basal Ganglia Diseases / Q000139:chemically induced / Q000188:drug therapy* / Q000517:prevention & control; D001569:Benzodiazepines / Q000627:therapeutic use; D002648:Child; D004198:Disease Susceptibility; D004311:Double-Blind Method; D004421:Dystonia / Q000139:chemically induced / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010276:Parasympatholytics / Q000627:therapeutic use*; D010302:Parkinson Disease, Secondary / Q000139:chemically induced / Q000188:drug therapy*; D011433:Propranolol / Q000627:therapeutic use; D011595:Psychomotor Agitation / Q000188:drug therapy*; D012306:Risk
D014150:Antipsychotic Agents; D010276:Parasympatholytics; D001569:Benzodiazepines; D011433:Propranolol; D000547:Amantadine